BioSpace News Archive

SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced today that the Company has submitted its formal application to list its common shares on the NASDAQ Capital Market.

Celebrating its 10th Anniversary, the Non-profit Organization will Also Host its Third Annual Conference in Boston on October 15

Ensysce Biosciences, Inc., a clinical stage drug delivery company, focusing on reducing deaths from opioid use, today announced that D. Lynn Kirkpatrick, Ph.D., Chief Executive Officer, will present at the Janney Healthcare Conference 2019 in New York on Monday September 9,

Teledyne Technologies Incorporated (NYSE:TDY) announced today that its subsidiary, Teledyne Digital Imaging, Inc., has acquired Micralyne Inc. (“Micralyne”). Based in Edmonton, Alberta, Canada, Micralyne is a privately-owned foundry providing Micro Electro Mechanical Systems or MEMS devices.

Dipharma Francis S.r.l., (Dipharma), a leading European manufacturer of Active Pharmaceutical Ingredients, announced today a series of changes in the leadership positions following the retirement of Mrs. Barbara Geinoz-Biazzi, Chairman.

North Shore University Hospital announced that it has begun offering genital gender confirmation surgery for members of the transgender/ gender non-conforming/non-binary community, the first hospital on Long Island to do so.

The Hyundai Hope On Wheels non-profit embarks on a nationwide tour this September to award new grants for pediatric cancer, surpassing $160 million in lifetime funding for research

Magnetic Insight, Inc., the leader in magnetic particle imaging (MPI) solutions, introduces the first commercially available MPI system with integrated X-ray computed tomography (CT), offering anatomical context to the newest breakthrough molecular imaging modality

As the single largest purchaser of goods and services, the federal government is using procurement to help Canadian small businesses succeed.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced that it proposes to offer $250 million aggregate principal amount of its convertible senior notes due 2024 (the “notes”), subject to market conditions and other factors.